MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that Harvest One Cannabis Inc. (CVE:HVST), which is 59% owned by MMJ, has released an update on its wholly-owned subsidiary United Greeneries Ltd..
MMJ PhytoTech Limited (ASX:MMJ) is pleased to provide the following update on the Company's strategic direction and proposed name change to "MMJ Capital Limited".
Oventus Medical Ltd (ASX:OVN) provide the latest Investor Presentation.
Boehringer Ingelheim and pharmaceutical research company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim is initiating the Phase IIa study ROBIN. This marks the beginning of the clinical development program for BI 1467335 in a second indication targeting a severe diabetes complication. An already ongoing Phase II clinical study program is investigating the compound in NASH.
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.
Traditional Therapy Clinics Limited (ASX:TTC) is pleased to advise that the Company is making significant progress on building its first series of greenfield clinics. There are five greenfield clinics being established whereby three of them are located in Guizhou, one in Hanan and one in Inner Mongolia.
Australian medical device company, Oventus Medical Ltd. (ASX:OVN) is pleased to release its Appendix 4E with its full year audited general purpose financial report for the period ending 30 June 2017.
